Application of PSMA targeted radionuclide drugs for the diagnosis and treatment of prostate cancer

Status

Recruiting

Phases

Early Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2100052545

Enrollment

Unknown

Registered

2021-10-30

Start date

2022-07-01

Completion date

Unknown

Last updated

2022-10-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

prostate cancer

Interventions

Radionuclide imaging group 1:68Ga-PSMA

Radionuclide imaging group 2:18F-PSMA

Radionuclide therapy group 1:177Lu –PSMA

Radionuclide therapy group 2:225Ac-PSMA

Eligibility

Sex/Gender

Male

Age

45 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1. Prostate cancer patients with self-consciousness, lying flat for 20 minutes and completing PET/CT general examination; 2. Patients with metastatic castration resistant prostate cancer, and PET / CT imaging showed significant PSMA targeted uptake lesions.

Exclusion criteria

Exclusion criteria: 1. Patients with severe liver and kidney failure, life crisis and unable to cooperate with the examination; 2. Patients with abnormal blood routine (indicating bone marrow suppression), and estimated survival less than 6 months.

Design outcomes

Primary

Measure	Time frame
Lesion detection rate;Progression free survival time;Overall survival time;	—

Countries

China

Contacts

Public ContactTao Weijing

The Affiliated Huai'an First People's Hospital of Nanjing Medical University

twjhayy@163.com+86 13861585848

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 8, 2026